Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00121420 · ClinicalTrials.gov registry record · Phase 2
Study of Motexafin Gadolinium With Whole Brain Radiation Therapy Followed by Stereotactic Radiosurgery Boost in the Treatment of Patients With Brain Metastases
A Phase 2 study, sponsored by Pharmacyclics.
- Terminated
- Registry status
- Phase 2
- Development phase
- 45
- Enrollment target
NCT00121420 is a Phase 2 study that was terminated before completion, run by Pharmacyclics. The registered enrollment target is 45 participants.
The verdict
NCT00121420, a Phase 2 study, was terminated before completion, sponsored by Pharmacyclics.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 45 participants
- Enrollment target
Study Summary
The primary purpose of the study is to evaluate if motexafin gadolinium with whole brain radiation therapy followed by a stereotactic radiosurgery boost is a safe and effective treatment.
Interventions
- DRUG Motexafin gadolinium
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00121420
The ClinicalTrials.gov registry entry for NCT00121420 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pharmacyclics, which has 54 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Motexafin gadolinium is the first listed.
NCT00121420 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00121420 about?
NCT00121420 is a clinical study titled "Study of Motexafin Gadolinium With Whole Brain Radiation Therapy Followed by Stereotactic Radiosurgery Boost in the Treatment of Patients With Brain Metastases". The primary purpose of the study is to evaluate if motexafin gadolinium with whole brain radiation therapy followed by a stereotactic radiosurgery boost is a safe and effective treatment.
What is the current status of trial NCT00121420?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 45 participants.
What interventions are being tested in trial NCT00121420?
The interventions under investigation include: Motexafin gadolinium (DRUG).
Who is sponsoring clinical trial NCT00121420?
This trial is sponsored by Pharmacyclics, which has 54 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.